Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
24 Jun 2024
24 Jun 2024
Historique:
medline:
24
6
2024
pubmed:
24
6
2024
entrez:
24
6
2024
Statut:
aheadofprint
Résumé
Several studies have demonstrated that patients who experience immune-related adverse events (irAE) as a result of immunotherapy treatment, exhibit significantly improved outcomes compared to patients without toxicity. Data regarding the impact of specific irAE is, however, currently lacking. This is a real-world single-site cohort of 415 advanced melanoma patients who were treated with immunotherapy as first-line between 2014 and 2020, with a median follow-up of 24.5 months. The most frequent irAEs were cutaneous (classified as non-vitiligo, n = 110, 26.5% and vitiligo, n = 48, 11.6%), rheumatologic (n = 68, 16.4%), gastrointestinal (n = 66, 15.9%), endocrine (n = 61, 14.7%), and hepatitis (n = 50, 12%). Specific irAE that were significantly associated with survival benefit were rheumatologic (hazard ratio 0.34 for PFS, P < 0.001; hazard ratio 0.38 for OS, P < 0.001), non-vitiligo cutaneous (hazard ratio 0.58 for PFS, P < 0.001; hazard ratio 0.54 for OS, P = 0.001), vitiligo (hazard ratio 0.30 for PFS, P < 0.001; hazard ratio 0.29 for OS, P < 0.001), and endocrine (hazard ratio 0.6 for PFS, P = 0.01; hazard ratio 0.52 for OS, P < 0.001). Other types if irAEs, such as colitis, hepatitis and others - do not present this correlation. . The occurrence of these specific irAEs may reflect a hyperactivated immune response and thus can serve as meaningful clinical biomarkers.
Identifiants
pubmed: 38913412
doi: 10.1097/CMR.0000000000000985
pii: 00008390-990000000-00158
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hodi FS, Chiarion -Sileni V, Lewis KD, Grob J, Rutkowski P, Lao CD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol 2022; 40 (16_suppl):9522–9522.
Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 2023; 41:3998–4003.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386:24–34.
Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med 2019; 66:119–119. https://www.frontiersin.org/articles/10.3389/fmed.2019.00119. [Accessed 11 August 2023]
doi: 10.3389/fmed.2019.00119.
Taylor J, Gandhi A, Gray E, Zaenker P. Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front Immunol 2023; 13:991433.
Loo K, Smithy JW, Postow MA, Betof Warner A. Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma. Front Immunol 2022; 12:810388. https://www.frontiersin.org/articles/10.3389/fimmu.2021.810388. [Accessed 11 August 2023]
doi: 10.3389/fimmu.2021.810388.
Seyhan AA, Carini C. Insights and strategies of melanoma immunotherapy: predictive biomarkers of response and resistance and strategies to improve response rates. IJMS 2023; 24:41. https://www.mdpi.com/1422-0067/24/1/41. [Accessed 11 August 2023]
Spiliopoulou P, Vornicova O, Genta S, Spreafico A. Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. IJMS 2023; 24:1294. https://www.mdpi.com/1422-0067/24/2/1294. [Accessed 11 August 2023]
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J ImmunoTher Cancer 2018; 6:32. https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0344-8. [Accessed 11 August 2023]
doi: 10.1186/s40425-018-0344-8.
Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 2017; 28:1130–1136.
OncoHost Ltd. PROPHETIC - Predicting responsiveness in oncology patients based on host response evaluation during anti cancer treatments. ClinicalTrials.gov; 2023. https://clinicaltrials.gov/study/NCT04056247. [Accessed 9 August 2023]
Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment—a review from the melanoma perspective and beyond. Front Immunol 2018; 9:1474.
Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35:785–792.
Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, et al. Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy. JAMA Netw Open 2022; 5:e2245596.
Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer 2020; 20:656.
Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, et al. Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis. Front Oncol 2021; 11:749064. https://www.frontiersin.org/articles/10.3389/fonc.2021.749064. [Accessed 11 August 2023]
doi: 10.3389/fonc.2021.749064.
Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, et al. Association between immune-related adverse events and survival in 319 stage IV melanoma patients treated with PD-1-based immunotherapy: an approach based on clinical chemistry. Cancers 2021; 13:6141.
Ye W, Olsson-Brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, et al. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Br J Cancer 2021; 124:1661–1669.
Dimitriou F, Staeger R, Ak M, Maissen M, Kudura K, Barysch MJ, et al. Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an institutional database analysis. Cancers 2021; 13:2931.
Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, et al. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer 2020; 132:61–70.
Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 2017; 12:1798–1805.
Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020; 18:87.
Eggermont AMM, Kicinski M, Blank CU, Mandalà M, Long GV, Atkinson V, et al. Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial. J Clin Oncol 2019; 37:2517–2517.
Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, et al. Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations. Front Immunol 2023; 14:1122430.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541–547.
Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A 2016; 113:E2383–E2392.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141–151.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291:319–322.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95:103208.
Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol 2021; 11:633032–633032. https://www.frontiersin.org/articles/10.3389/fonc.2021.633032. [Accessed 13 August 2023]
doi: 10.3389/fonc.2021.633032.
Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33:773–781.
Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151:1206–1212.
Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol 2019; 5:906–908.
Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol 2023; 14:1071983–1071983. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1071983. [Accessed 13 August 2023]
doi: 10.3389/fimmu.2023.1071983.
Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis 2021; 12:2040622320976996.
Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer Oxf Engl 1990; 2018:105.
Chan KK, Tirpack A, Vitone G, Benson C, Nguyen J, Ghosh N, et al. Higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression: results from an observational registry. ACR Open Rheumatol 2020; 2:595–604.
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 2020; 19:102595.
Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis 2021; 13:1759720X2110069–175972211006963.
Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 2018; 67:175–182.